| [1] |
Kung CW, Chou YH. Acute kidney disease: an overview of the epidemiology, pathophysiology, and management [J]. Kidney Res Clin Pract, 2023, Epub ahead of print.
|
| [2] |
Guzzi F, Cirillo L, Roperto RM, et al. Molecular mechanisms of the acute kidney injury to chronic kidney disease transition: an updated view [J]. Int J Mol Sci, 2019, 20(19): 4941.
|
| [3] |
Thakar CV, Christianson A, Himmelfarb J, et al. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus [J]. Clin J Am Soc Nephrol, 2011, 6(11): 2567-2572.
|
| [4] |
Kurzhagen JT, Dellepiane S, Cantaluppi V, et al. AKI: an increasingly recognized risk factor for CKD development and progression [J]. J Nephrol, 2020, 33(6): 1171-1187.
|
| [5] |
Saranya GR, Viswanathan P. Gut microbiota dysbiosis in AKI to CKD transition [J]. Biomed Pharmacother, 2023, 161: 114447.
|
| [6] |
Chen JY, Tsai I, Pan HC, et al. The impact of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers on clinical outcomes of acute kidney disease patients: a systematic review and meta-analysis [J]. Front Pharmacol, 2021, 12: 665250.
|
| [7] |
Ciarambino T, Crispino P, Giordano M. Gender and renal insufficiency: opportunities for their therapeutic management? [J]. Cells, 2022, 11(23): 3820.
|
| [8] |
Wang Z, Zhang C. From AKI to CKD: maladaptive repair and the underlying mechanisms [J]. Int J Mol Sci, 2022, 23(18): 10880.
|
| [9] |
McWilliam SJ, Wright RD, Welsh GI, et al. The complex interplay between kidney injury and inflammation [J]. Clin Kidney J, 2021, 14(3): 780-788.
|
| [10] |
Tinti F, Lai S, Noce A, et al. Chronic kidney disease as a systemic inflammatory syndrome: update on mechanisms involved and potential treatment [J]. Life (Basel), 2021, 11(5): 419.
|
| [11] |
Wu YS, Liang S, Li DY, et al. Cell cycle dysregulation and renal fibrosis [J]. Front Cell Dev Biol, 2021, 9: 714320.
|
| [12] |
Yang L, Besschetnova TY, Brooks CR, et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury [J]. Nat Med, 2010, 16(5): 535-543.
|
| [13] |
Zhang X, Agborbesong E, Li X. The role of mitochondria in acute kidney injury and chronic kidney disease and its therapeutic potential [J]. Int J Mol Sci, 2021, 22(20): 11253.
|
| [14] |
Bartoszewska S, Collawn JF. Unfolded protein response (UPR) integrated signaling networks determine cell fate during hypoxia [J]. Cell Mol Biol Lett, 2020, 25: 18.
|
| [15] |
Chen F, Gao Q, Wei A, et al. Histone deacetylase 3 aberration inhibits Klotho transcription and promotes renal fibrosis [J]. Cell Death Differ, 2021, 28(3): 1001-1012.
|
| [16] |
Fontecha-Barriuso M, Martin-Sanchez D, Ruiz-Andres O, et al. Targeting epigenetic DNA and histone modifications to treat kidney disease [J]. Nephrol Dial Transplant, 2018, 33(11): 1875-1886.
|
| [17] |
Zhou Q, Chen W, Yu XQ. Long non-coding RNAs as novel diagnostic and therapeutic targets in kidney disease [J]. Chronic Dis Transl Med, 2020, 5(4): 252-257.
|
| [18] |
Venkatachalam MA, Weinberg JM, Kriz W, et al. Failed tubule recovery, AKI-CKD transition, and kidney disease progression [J]. J Am Soc Nephrol, 2015, 26(8): 1765-1776.
|
| [19] |
Zhu Z, Hu J, Chen Z, et al. Transition of acute kidney injury to chronic kidney disease: role of metabolic reprogramming [J]. Metabolism, 2022, 131: 155194.
|
| [20] |
Baudoux T, Jadot I, Declèves AE, et al. Experimental aristolochic acid nephropathy: a relevant model to study AKI-to-CKD transition [J]. Front Med (Lausanne), 2022, 9: 822870.
|
| [21] |
Aggarwal D, Singh G. Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats [J]. Naunyn Schmiedebergs Arch Pharmacol, 2020, 393(4): 615-627.
|
| [22] |
Ciarambino T, Crispino P, Giordano M. Gender and renal insufficiency: opportunities for their therapeutic management? [J]. Cells, 2022, 11(23): 3820.
|
| [23] |
McCoy IE, Hsu JY, Bonventre JV, et al. Acute kidney injury associates with long-term increases in plasma TNFR1, TNFR2, and KIM-1: findings from the CRIC study [J]. J Am Soc Nephrol, 2022, 33(6): 1173-1181.
|
| [24] |
Tuan PNH, Quyen DBQ, Van Khoa H, et al. Serum and urine neutrophil gelatinase-associated lipocalin levels measured at admission predict progression to chronic kidney disease in sepsis-associated acute kidney injury patients [J]. Dis Markers, 2020, 2020: 8883404.
|
| [25] |
Cooper DS, Claes D, Goldstein SL, et al. Follow-up renal assessment of injury long-term after acute kidney injury (FRAIL-AKI) [J]. Clin J Am Soc Nephrol, 2016, 11(1): 21-29.
|
| [26] |
Ichikawa D, Kamijo-Ikemori A, Sugaya T, et al. Utility of urinary tubular markers for monitoring chronic tubulointerstitial injury after ischemia-reperfusion [J]. Nephrology (Carlton), 2018, 23(4): 308-316.
|
| [27] |
Cho WY, Lim SY, Yang JH, et al. Urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 as biomarkers of patients with established acute kidney injury [J]. Korean J Intern Med, 2020, 35(3): 662-671.
|
| [28] |
Zheng Z, Xu K, Li C, et al. NLRP3 associated with chronic kidney disease progression after ischemia/reperfusion-induced acute kidney injury [J]. Cell Death Discov, 2021, 7(1): 324.
|
| [29] |
Xing Z, Gong K, Hu N, et al. The reduction of uromodulin, complement factor H, and their interaction is associated with acute kidney injury to chronic kidney disease transition in a four-time cisplatin-injected rat model [J]. Int J Mol Sci, 2023, 24(7): 6636.
|
| [30] |
Menez S, Moledina DG, Garg AX, et al. Results from the TRIBE-AKI study found associations between post-operative blood biomarkers and risk of chronic kidney disease after cardiac surgery [J]. Kidney Int, 2021, 99(3): 716-724.
|
| [31] |
Liu Z, Tan RJ, Liu Y. The many faces of matrix metalloproteinase-7 in kidney diseases [J]. Biomolecules, 2020, 10(6): 960.
|
| [32] |
Yin J, Wang F, Kong Y, et al. Antithrombin III prevents progression of chronic kidney disease following experimental ischaemic-reperfusion injury [J]. J Cell Mol Med, 2017, 21(12): 3506-3514.
|
| [33] |
Zhao JY, Wu YB. Huaier extract attenuates acute kidney injury to chronic kidney disease transition by inhibiting endoplasmic reticulum stress and apoptosis via miR-1271 upregulation [J]. Biomed Res Int, 2020, 2020: 9029868.
|
| [34] |
Wu M, Chen W, Miao M, et al. Anti-anemia drug FG4592 retards the AKI-to-CKD transition by improving vascular regeneration and antioxidative capability [J]. Clin Sci (Lond), 2021, 135(14): 1707-1726.
|
| [35] |
Nishida K, Watanabe H, Murata R, et al. Recombinant long-acting thioredoxin ameliorates AKI to CKD transition via modulating renal oxidative stress and inflammation [J]. Int J Mol Sci, 2021, 22(11): 5600.
|
| [36] |
Chen DQ, Cao G, Zhao H, et al. Combined melatonin and poricoic acid A inhibits renal fibrosis through modulating the interaction of Smad3 and β-catenin pathway in AKI-to-CKD continuum [J]. Ther Adv Chronic Dis, 2019, 10: 2040622319869116.
|
| [37] |
Abdelmageed MM, Kefaloyianni E, Arthanarisami A, et al. TNF or EGFR inhibition equally block AKI-to-CKD transition: opportunities for etanercept treatment [J]. Nephrol Dial Transplant, 2023, 38(5): 1139-1150.
|
| [38] |
Zahan MS, Ahmed KA, Moni A, et al. Kidney protective potential of lactoferrin: pharmacological insights and therapeutic advances [J]. Korean J Physiol Pharmacol, 2022, 26(1): 1-13.
|
| [39] |
Jia Y, Kang X, Tan L, et al. Nicotinamide mononucleotide attenuates renal interstitial fibrosis after AKI by suppressing tubular DNA damage and senescence [J]. Front Physiol, 2021, 12: 649547.
|
| [40] |
Lok SWY, Yiu WH, Li H, et al. The PAR-1 antagonist vorapaxar ameliorates kidney injury and tubulointerstitial fibrosis [J]. Clin Sci (Lond), 2020, 134(21): 2873-2891.
|
| [41] |
Yu Y, Chen M, Guo Q, et al. Human umbilical cord mesenchymal stem cell exosome-derived miR-874-3p targeting RIPK1/PGAM5 attenuates kidney tubular epithelial cell damage [J]. Cell Mol Biol Lett, 2023, 28(1): 12.
|
| [42] |
Mapuskar KA, Vasquez-Martinez G, Mayoral-Andrade G, et al. Mitochondrial oxidative metabolism: an emerging therapeutic target to improve CKD outcomes [J]. Biomedicines, 2023, 11(6): 1573.
|
| [43] |
Li C, Shen Y, Huang L, et al. Senolytic therapy ameliorates renal fibrosis postacute kidney injury by alleviating renal senescence [J]. FASEB J, 2021, 35(1): e21229.
|
| [44] |
Li J, Gong X. Tetramethylpyrazine: an active ingredient of Chinese herbal medicine with therapeutic potential in acute kidney injury and renal fibrosis [J]. Front Pharmacol, 2022, 13: 820071.
|
| [45] |
Kurata Y, Nangaku M. Use of antibiotics as a therapeutic approach to prevent AKI-to-CKD progression [J]. Kidney Int, 2023, 104(3): 418-420.
|